Found 77 articles for: "Leon H. Kircik"
INDIVIDUAL ARTICLE: Vehicles Matter!
February 2024 | Volume 23 | Issue 2 | Supplement Individual Articles | SF378969s3 | Copyright © February 2024
Patient Preference for Calcipotriene and Betamethasone Dipropionate Cream Versus Foam for the Topical Treatment of Psoriasis: A Pilot Study
March 2023 | Volume 22 | Issue 3 | Original Article | 271 | Copyright © March 2023
Background: The well-established sequential use of topical calcipotriene and topical betamethasone dipropionate in combination has been shown to provide greater benefit than eith...
Read MoreSupplement Individual Article: Oldie But Goodie
January 2023 | Volume 22 | Issue 1 | Supplement Individual Articles | 3446172 | Copyright © January 2023
Research over the past several years has elucidated the pathophysiology of psoriasis, yielding both new treatment options and enhanced knowledge of the mechanisms of action of existing treatments....
Read MoreSupplement Individual Article: A Reappraisal of Fixed-Combination Halobetasol Propionate and Tazarotene for the Treatment of Psoriasis: Biological Underpinnings, Therapeutic Mechanisms, and Economic Considerations
January 2023 | Volume 22 | Issue 1 | Supplement Individual Articles | 3446174 | Copyright © January 2023
Psoriasis is a complex inflammatory disease, which can be triggered by the interplay among keratinocytes, various immune cells, and even dermal vascular endothelial cells. Understanding of the key pla...
Read MoreSUPPLEMENT INDIVIDUAL ARTICLES: Update on Truncal Acne: A Review of Treatments for a Neglected Disease and the Re-Emergence of Tazarotene
December 2022 | Volume 21 | Issue 12 | Supplement Individual Articles | SF3446185 | Copyright © December 2022
Acne vulgaris of the trunk carries with it a major psychosocial impact and an unmet need for adequate management. Approximately 50% of patients with facial acne also exhibit involvement of the back, c...
Read MoreSUPPLEMENT INDIVIDUAL ARTICLES: "Vehicles Matter" in the Treatment of Truncal Acne
December 2022 | Volume 21 | Issue 12 | Supplement Individual Articles | SF3446183 | Copyright © December 2022
Among the general population and arguably among most dermatologists, the word acne calls to mind images of a teenager with papules and pustules on the face. Yet, we know that acne is not just a diseas...
Read MoreThe Maintenance Effect of Calcipotriene 0.05% and Betamethasone Dipropionate 0.064% (Cal/BD) Aerosol Foam in Combination With Apremilast
April 2022 | Volume 21 | Issue 4 | Original Article | 381 | Copyright © April 2022
Even in light of significant recent therapeutic advancements, many patients with psoriasis will use a combination of treatments at some point in the disease course. Despite the frequency with which co...
Read MoreIn Vitro Rheology Predicts Improved Spreadability of Tazarotene 0.045% Lotion Versus Trifarotene 0.005% Cream
March 2022 | Volume 21 | Issue 3 | Original Article | 250 | Copyright © March 2022
Background: Intrinsic properties of vehicles used to deliver topical therapies can profoundly impact drug penetration, efficacy, patient acceptance, and treatment adherence. Therefore...
Read MoreAn Open-Label Pilot Study to Investigate Safety and Efficacy of Fixed Combination Tazarotene 0.045% and Halobetasol Propionate 0.01% Lotion for the Treatment of Scalp Psoriasis
November 2021 | Volume 20 | Issue 11 | Original Article | 1191 | Copyright © November 2021
Up to 80% of individuals with plaque psoriasis have scalp involvement, which can have a significant impact on the quality of life of affected individuals. Despite advancements in psoriasis therapeutic...
Read MoreINDIVIDUAL ARTICLE: Safety and Tolerability of Topical Agents for Actinic Keratosis: A Systematic Review of Phase 3 Clinical Trials
October 2021 | Volume 20 | Issue 10 | Supplement Individual Articles | s4s4 | Copyright © October 2021
Background: Topical agents for actinic keratosis (AK), along with cryotherapy and phototherapy, are the most commonly used therapies for areas of skin with multiple AKs. Multiple opti...
Read MoreARTICLE: Why Absorica LD?
May 2021 | Volume 20 | Issue 5 | Supplement Individual Articles | 3s | Copyright © May 2021
Oral Sarecycline for Treatment of Papulopustular Rosacea: Results of a Pilot Study of Effectiveness and Safety
April 2021 | Volume 20 | Issue 4 | Original Article | 426 | Copyright © April 2021
Background: Cutaneous rosacea is a common inflammatory skin disorder that often presents with facial papulopustular lesions that are frequently bothersome to patients. Studies have sh...
Read MoreEffects of Tazarotene 0.045% Lotion on Quality of Life in Patients With Moderate-to-Severe Acne
November 2020 | Volume 19 | Issue 11 | Original Article | 1086 | Copyright © November 2020
Background: In two phase 3 trials (NCT03168334, NCT03168321), participants with moderate-to-severe acne had significant symptom improvements after 12 weeks of treatment with tazaroten...
Read MoreARTICLE: Oral Tetracyclines and Acne: A Systematic Review for Dermatologists
November 2020 | Volume 19 | Issue 11 | Supplement Individual Articles | s6 | Copyright © November 2020
Oral tetracyclines are the most widely prescribed systemic antibiotic for acne. Synthesis of efficacy and safety of traditional and novel oral tetracyclines is highly informative to clinical practice....
Read MoreARTICLE: A Novel Antibiotic Just for Acne
November 2020 | Volume 19 | Issue 11 | Supplement Individual Articles | s5 | Copyright © November 2020
Dermatologists consistently rank as the most frequent prescribers of systemic antibiotics, and one of the most common diagnoses for which we recommend these agents is acne vulgaris. Up to three quarte...
Read MoreOnce-Daily Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Sex
August 2020 | Volume 19 | Issue 8 | Original Article | 777 | Copyright © August 2020
Background: Two identical phase 3 randomized, double-blind, vehicle-controlled, 12-week studies (NCT03168321 and NCT03168334) demonstrated the efficacy and safety of tazarotene 0.045%...
Read MoreHalobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Lower Extremities
April 2020 | Volume 19 | Issue 4 | Original Article | 389 | Copyright © April 2020
Background: Plaque psoriasis can occur in all body regions, with the trunk and extremities among the most commonly affected areas. A fixed combination halobetasol propionate 0.01%/taz...
Read MoreARTICLE: Game Changer in Acne Treatment
March 2020 | Volume 19 | Issue 3 | Supplement Individual Articles | 28 | Copyright © March 2020
Of the four primary pathogenic factors that drive acne vulgaris—androgen excess, increased sebum production, faulty keratinization, and overgrowth of C. acnes—androgen excess has been the ...
Read MoreEffect of Calcipotriene/Betamethasone Dipropionate 0.005%/0.064% Foam on Target Lesions in Plaque Psoriasis: A Post-Hoc Analysis
February 2020 | Volume 19 | Issue 2 | Original Article | 121 | Copyright © February 2020
OBJECTIVE: Investigate the effect of fixed-combination calcipotriene 0.005% plus betamethasone dipropionate 0.064% (Cal/BD) foam on target lesion severity in plaque psoriasis.
DESIGN: Post-hoc a...
Read MoreARTICLE: Clinical Insights About the Role of Skin pH in Inflammatory Dermatological Conditions Introduction
December 2019 | Volume 18 | Issue 12 | Supplement Individual Articles | 212 | Copyright © December 2019
There was a time in the not so distant past that when we were asked about skin care, we would advise any patient to “use a moisturizer.” This meant going to the local drug store and purcha...
Read More
